Skip to search formSkip to main contentSkip to account menu

Labetuzumab-SN-38 Immunoconjugate IMMU-130

Known as: ADC IMMU-130, Antibody-Drug Conjugate IMMU-130, hMN14-SN38 
An antibody-drug conjugate (ADC) containing labetuzumab, a mildly reduced, anti-CEACAM5 humanized monoclonal antibody, conjugated to the potent… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Towards guided biopsy using endoscopic NIR fluorescence imaging and OCT by cancer-specific fluorescent antibodies (Conference Presentation)
Determining cancer phenotypes early in the development of the disease is fundamental to increase the efficacy of therapy. To this… 
2017
2017
Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)
Labetuzumab govitecan (IMMU-130), an antibody–drug conjugate (ADC) with an average of 7.6 SN-38/IgG, was evaluated for its… 
2017
2017
Abstract 4081: Superior SN-38 pharmacodynamic and tumor-accretion profiles of labetuzumab govitecan (IMMU-130)versusirinotecan in experimental human colonic cancer models
BACKGROUND: IMMU-130 is an antibody-drug conjugate (ADC) undergoing clinical investigation in patients with metastatic colorectal… 
2015
2015
A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing…
2505 Background: Combination chemotherapies with 5-FU, irinotecan, oxaliplatin, anti-VEGF, and anti-EGFR agents have improved the… 
2015
2015
IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38 targeting CEACAM5 antigen: Preclinical basis for clinical activity in metastatic colorectal cancer (mCRC).
625 Background: IMMU-130 is a CEACAM5-targeted ADC, labetuzumab-SN-38, with the drug being the active form of the topoisomerase I… 
2009
2009
A pharmacogenetic UGT1A1 dose-escalation study for recurrent and refractory gynecologic cancer patients treated with combination therapy of irinotecan and cisplatin.
e16536 Background: In addition to polymorphisms of UGT1A1*28, UGT1A1*6 has been recognized as a risk factor for severe irinotecal… 
2007
2007
Safety and efficacy of repeated anti-CEA radioimmunotherapy (RAIT) with 131I-labetuzumab post salvage resection of colorectal liver metastases
14507 Background: As shown recently (JCO 2005; 23:6763–70), a single application of RAIT improved both, median overall survival… 
Highly Cited
2004
Highly Cited
2004
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN‐38
The uridine diphosphate glucuronosyltransferase (UGT) 1A1 and 1A9 isoforms are involved in the phase II biotransformation of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)